Welcome to our dedicated page for NKGen Biotech news (Ticker: NKGN), a resource for investors and traders seeking the latest updates and insights on NKGen Biotech stock.
NKGen Biotech Inc (NKGN) is a clinical-stage biotechnology company advancing natural killer cell therapies for cancer and neurodegenerative diseases. This page serves as the definitive source for official updates on clinical trials, regulatory developments, and research breakthroughs.
Investors and researchers will find timely announcements about NKGen's pipeline progress, including its lead candidates SNK02 and troculeucel. The curated news collection covers critical milestones: clinical data readouts, partnership agreements, manufacturing advancements, and scientific presentations validating NK cell therapy efficacy.
All content is sourced directly from company releases and verified industry publications. Regular updates ensure stakeholders maintain current awareness of NKGen's work in non-genetically modified NK cell platforms and their applications across oncology and neurological conditions.
Bookmark this page for structured access to NKGN's evolving story in immunotherapy. Check back frequently for developments that could impact both patient care and investment perspectives in cutting-edge biotherapeutics.
NKGen Biotech (OTC: NKGN) has administered the first dose of troculeucel, an expanded autologous NK cell therapy, to a mild-stage Alzheimer's patient under FDA compassionate use authorization. The patient had shown continued cognitive decline despite treatment with lecanemab, an amyloid-targeting therapy.
The treatment is being conducted in collaboration with Dr. Anita Fletcher at AdventHealth Neuroscience Institute. While NKGen's current Phase 2a trial focuses on moderate-stage Alzheimer's, this marks their first potential expansion into mild Alzheimer's treatment, particularly for patients not responding to first-line therapies.
Troculeucel has demonstrated promising characteristics, including the ability to cross the blood-brain barrier and improve levels of various proteins in cerebrospinal fluid while reducing neuroinflammation.
NKGen Biotech (OTC: NKGN) announced that Chairman & CEO Paul Y. Song, M.D. has made a personal investment of $2.65 million in the company through shares and warrants. The funding comes from proceeds of Dr. Song's recent sale of Fuse Biotherapeutics, which he co-founded. This investment supplements $3.0 million in funding advances from AlpineBrook Capital in 2025, beyond their previous $5.5 million proceeds and $4 million commitments in convertible notes.
The new capital will be used to accelerate NKGen's Phase 2 clinical trial for Alzheimer's Disease, reduce company payables, and cover working capital and compliance-related expenses. The AlpineBrook advances are secured by personal guarantees from Dr. Song and Interim CFO James Graf.
NKGen Biotech (OTC: NKGN) announced an upcoming presentation of Phase 1 clinical data for troculeucel, their cryopreserved expanded autologous NK cell therapy for moderate Alzheimer's disease (AD), at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting. The presentation, titled "Use of Expanded Non-genetically Modified Natural Killer Cells (Troculeucel) with Enhanced Cytotoxicity in Patients with Alzheimer's Disease. Preliminary Clinical and Biomarker Results," will be delivered by Dr. Paul Y. Song on May 14, 2025, at 2:30 PM CT in New Orleans.
NKGen Biotech (OTC: NKGN) has announced that its Chairman and CEO, Dr. Paul Y. Song, will present at the 7th China International Biotechnology Conference & Exhibition (BIOTEC-CHINA 2025) in Beijing from April 16-18, 2025.
The presentation, scheduled for April 17, 2025, at 10:20 am CST, will focus on troculeucel, the company's NK cell therapeutic treatment for Alzheimer's and Parkinson's disease. Dr. Song will discuss promising results from Phase 1 clinical trials and compassionate use cases, along with updates on their ongoing Phase 1/2a clinical trial for moderate Alzheimer's disease.
BIOTEC-CHINA 2025 is expected to attract approximately 1,500 biotechnology and pharmaceutical professionals, offering networking opportunities and covering various life science topics including drug discovery, biomanufacturing, genomics, nanotechnology, and cell therapy.
NKGen Biotech (OTC: NKGN) presented updated Phase 1 clinical data for troculeucel, their NK cell therapy for moderate Alzheimer's disease (AD), at AD/PD™ 2025. The trial administered the highest dose of 6 billion cells every three weeks to three patients with moderate AD.
Key findings after 12 months: Two patients completed all 17 doses, showing improvement from moderate to mild AD within 3 months. One patient achieved a CDR-SB score of 4.5, near the mild cognitive impairment threshold. No drug-related adverse reactions were reported. All patients showed decreased GFAP levels in CSF and plasma at 6 months, while the two completing patients demonstrated improved Amyloid Beta 42/40 ratios at 12 months.
The company is now proceeding with the randomized, placebo-controlled Phase 2a portion of the study, expecting significant cognitive and biomarker differences between treatment and placebo groups within 6 months.
NKGen Biotech (OTC: NKGN) has announced its upcoming presentation at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025), scheduled for April 1-5, 2025, in Vienna, Austria. The event will also be available online.
Dr. Paul Y. Song, Chairman and CEO of NKGen, will present updated data from their Phase 1/2a clinical trial of troculeucel NK cell therapy for moderate Alzheimer's disease. The presentation will cover three-month cognitive and biomarker results from the Phase 1 cohort, along with new six-month analysis data.
AD/PD™ 2025 is a leading international conference that gathered over 4,700 participants from 70+ countries and featured 2,250 abstracts in 2024. The conference serves as a platform for experts to share the latest developments in Alzheimer's and Parkinson's research, clinical trials, and treatments.
NKGen Biotech (OTC: NKGN) announced its participation in the 13th Annual Alzheimer's & Parkinson's Drug Development Summit in Boston from March 18-20, 2025. Chairman and CEO Paul Y. Song will present on troculeucel, the company's autologous, non-genetically modified NK cell therapy for neurodegenerative diseases.
The presentation will focus on troculeucel's mechanism and promising Phase 1 clinical trial results, which led to FDA Fast Track designation for moderate Alzheimer's Disease and a new Investigational New Drug designation for Parkinson's Disease. The company also plans to explore troculeucel's potential in Frontotemporal Dementia and post-stroke/traumatic brain injury treatment.
The Summit, featuring over 150 experts, is the only industry-focused event covering the complete drug development process from discovery to commercialization, highlighting advancements in neurodegenerative therapeutics, presymptomatic diagnosis, and new treatment modalities.
NKGen Biotech (NKGN) announced its delisting from Nasdaq Global Market effective March 4, 2025, due to non-compliance with market value requirements. The company will transition to OTC Markets starting March 5, 2025, trading under symbols 'NKGN' for common stock and 'NKGNW' for warrants.
The company has cancelled its previously planned 1-for-6 reverse stock split and intends to apply for the OTCQX platform, maintaining SEC reporting compliance. NKGen's Phase 2a Alzheimer's trial enrollment is expected to complete by Q2 end, with initial readout planned for late 2025.
Despite challenges related to their former parent company NKMAX's financial restructuring, NKGen highlighted progress in their Alzheimer's program, including FDA Fast Track designation, Phase 1 results publication, and presentations at major conferences in 2024. The company aims to eventually re-list on Nasdaq once meeting listing requirements.
NKGen Biotech (NKGN) has administered its first dose of troculeucel, an expanded autologous NK cell therapy, to a stroke patient under an FDA-cleared compassionate use program. The treatment, administered at George Washington University Medical Center, marks the company's initial exploration into stroke treatment applications.
The initiative, led in collaboration with Dr. Dimitri Sigounas and Dr. Amarendra K. Neppalli, aims to investigate troculeucel's potential in reducing chronic neuroinflammation in post-stroke patients. This is particularly significant as stroke remains the second leading cause of death and long-term disability, with 20% of survivors developing dementia.
The company's previous Alzheimer's trials demonstrated troculeucel's ability to cross the blood-brain barrier and reduce cerebrospinal fluid levels of brain injury markers GFAP and NfL. This compassionate use program represents a stepping stone toward a possible full IND application for stroke treatment.
FAQ
What is the current stock price of NKGen Biotech (NKGN)?
What is the market cap of NKGen Biotech (NKGN)?
